Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep 18;22(18):10105.
doi: 10.3390/ijms221810105.

Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia

Thomas Cluzeau  1   2   3 , Michael Loschi  1   2 , Pierre Fenaux  3   4 , Rami Komrokji  5 , David A Sallman  5
Affiliations
Review

Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia

Thomas Cluzeau et al. Int J Mol Sci. .

Abstract

Targeting TP53 mutated myelodysplastic syndromes and acute myeloid leukemia remains a significant unmet need. Recently, new drugs have attempted to improve the outcomes of this poor molecular subgroup. The aim of this article is to review all the current knowledge using active agents including hypomethylating agents with venetoclax, eprenetapopt or magrolimab. We include comprehensive analysis of clinical trials to date evaluating these drugs in TP53 myeloid neoplasms as well as discuss future novel combinations for consideration. Additionally, further understanding of the unique clinicopathologic components of TP53 mutant myeloid neoplasms versus wild-type is critical to guide future study. Importantly, the clinical trajectory of patients is uniquely tied with the clonal burden of TP53, which enables serial TP53 variant allele frequency analysis to be a critical early biomarker in investigational studies. Together, significant optimism is now possible for improving outcomes in this patient population.

Keywords: AML; MDS; TP53; eprenetapopt; magrolimab.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Sallman D.A., Komrokji R., Vaupel C., Cluzeau T., Geyer S.M., McGraw K.L., Al Ali N.H., Lancet J., McGinniss M.J., Nahas S., et al. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes. Leukemia. 2016;30:666–673. doi: 10.1038/leu.2015.304. - DOI - PMC - PubMed
    1. Haase D., Stevenson K.E., Neuberg D., Maciejewski J.P., Nazha A., Sekeres M.A., Ebert B.L., Garcia-Manero G., Haferlach C., Haferlach T., et al. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia. 2019;33:1747–1758. doi: 10.1038/s41375-018-0351-2. - DOI - PMC - PubMed
    1. Papaemmanuil E., Gerstung M., Bullinger L., Gaidzik V.I., Paschka P., Roberts N.D., Potter N.E., Heuser M., Thol F., Bolli N., et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N. Engl. J. Med. 2016;374:2209–2221. doi: 10.1056/NEJMoa1516192. - DOI - PMC - PubMed
    1. Lindsley R.C., Saber W., Mar B.G., Redd R., Wang T., Haagenson M.D., Grauman P.V., Hu Z.-H., Spellman S.R., Lee S.J., et al. Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. N. Engl. J. Med. 2017;376:536–547. doi: 10.1056/NEJMoa1611604. - DOI - PMC - PubMed
    1. Yoshizato T., Nannya Y., Atsuta Y., Shiozawa Y., Iijima-Yamashita Y., Yoshida K., Shiraishi Y., Suzuki H., Nagata Y., Sato Y., et al. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: Impact on outcome of stem cell transplantation. Blood. 2017;129:2347–2358. doi: 10.1182/blood-2016-12-754796. - DOI - PMC - PubMed

MeSH terms